Anti-cytokine antibodies for rheumatic diseases

F. Atzeni, P. Sarzi-Puttini

Research output: Contribution to journalArticlepeer-review


Improved knowledge regarding the pathogenetic mechanisms involved in autoimmune diseases has contributed to the development of biological therapies, with advances in cytokine research in particular revolutionizing the treatment of several autoimmune diseases. Anti-TNF agents are the most promising drugs for reducing symptoms, slowing or arresting joint damage, and preventing functional disability in patients with rheumatoid arthritis who fail to respond to standard disease-modifying antirheumatic drugs. Anti-TNF agents may also be useful in the treatment of other rare disorders, such as various forms of vasculitis, polymyositis and dermatomyositis. However, clinical trials of TNF inhibitors and inhibitors of the proinflammatory cytokines IL-1, IL-6, IL-12, IL-15, IL-17 and IL-23 demonstrated that the activity of such compounds is accompanied by a series of adverse events that needs to be addressed. This review describes the efficacy and adverse events associated with anti-cytokine treatments for autoimmune rheumatic diseases.

Original languageEnglish
Pages (from-to)1204-1211
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Issue number11
Publication statusPublished - Nov 2009


  • Anti-cytokine antibody
  • Autoimmune disease
  • MAb
  • Rheumatoid arthritis
  • TNF

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Anti-cytokine antibodies for rheumatic diseases'. Together they form a unique fingerprint.

Cite this